First Patient Treated in Clinical Trial of CX-2009 for Prostate, Other Solid Cancers

First Patient Treated in Clinical Trial of CX-2009 for Prostate, Other Solid Cancers
The first patient has been treated with CytomX Therapeutics' investigational Probody drug conjugate CX-2009 in a new phase 1/2 clinical trial. The drug candidate is designed to target a surface molecule found in a number of solid tumors, including castration-resistant prostate cancer. Developed by CytomX, Probody therapeutics are engineered to bind selectively to cancer cells and not healthy cells to reduce toxicity while remaining effective at fighting malignant tumors. To achieve this level of specificity, the technology takes advantage of the presence of tumor-released enzymes that have the capacity to cleave a small protein that masks the drug target binding site. Because these enzymes are found only in the tumor microenvironment, the drug's bind
Subscribe or to access all post and page content.

2 comments

  1. Sharon Steiner says:

    My husband has prostate cancer that has metastasized to the bone following a botched biopsy. He is 70 years old. Side effects of his medications (Zytiga w/ Prednisone) have resulted in Type2 Diabetes. Is he a candidate for the NCTO3149549 CX-2009 drug trial? Thank you.

    • Alice Melão says:

      Dear Sharon, According with the information available on the website http://www.clinicatrials.gov I would say that your husband would not be eligible for the trial. They specify that participants can’t have: 1) Serious concurrent illness or 2) History of or current active autoimmune diseases. But I am not a doctor and so you can look for additional information directly with the trial contact: Lori Carman (650-515-3185) [email protected]

Leave a Comment

Your email address will not be published. Required fields are marked *